Abstracts tagged "Lupus nephritis"

Abstract Number: 65 • 2019 ACR/ARP Annual Meeting
CD6 Modulation Ameliorates Skin and Kidney Disease in a Spontaneous Murine Model of SLE
Samantha Chalmers¹, Sayra Garcia ¹, Rajalakshmy Ayilam Ramachandran ², Chandra Mohan ², Jeanette Ampudia ³, Cherie Ng ³, Stephen Connelly ³ and Chaim Putterman ⁴, ¹Albert Einstein College of Medicine, Bronx, NY, ²University of Houston, Houston, ³Equillium, Inc, San Diego, CA, ⁴Albert Einstein College of Medicine, New York, NY
Background/Purpose: T cells are an important contributor the pathogenesis of SLE and its various end organ manifestations. Thus, they present themselves as potential therapeutic targets;…
Abstract Number: 1128 • 2019 ACR/ARP Annual Meeting
Physician-Patient Interaction and Medication Adherence in Lupus Nephritis
Sofia Georgopoulou¹, Louise Nel ², Shirish Sangle ² and David D'Cruz ³, ¹King's College London & The Royal Marsden Hospital NHS Foundation Trust, London, England, United Kingdom, ²Guy's & St Thomas' Hospitals NHS Foundation Trust, London, England, United Kingdom, ³The Louise Coote Lupus Unit, Guy's Hospital, London, England, United Kingdom
Background/Purpose: The quality of physician-patient interaction can have a significant impact on medication adherence. Little is known about this relationship in patients with lupus nephritis…
Abstract Number: 2542 • 2019 ACR/ARP Annual Meeting
An Updated Meta-Analysis of the Efficacy and Safety of Mycophenolate Mofetil in the Induction Treatment of Chinese Patients with Lupus Nephritis
Minlin Zhou¹, Yang yang ², Xiaoyan Han ², Xin Yu ² and Haitao zhang ¹, ¹National Clinical Research Center of Kidney Diseases, Jinling Hospital, Nanjing University School of Medicine, Nanjing, China (People's Republic), ²Shanghai Roche Pharmaceuticals Ltd, Shanghai, China (People's Republic)
Background/Purpose: Achieving clinical remission while reducing toxicity are primary objectives in the treatment of lupus nephritis (LN). Mycophenolate mofetil (MMF) has demonstrated efficacy benefits with…
Abstract Number: 66 • 2019 ACR/ARP Annual Meeting
Amelioration of Immune Complex-Mediated Glomerulonephritis by CD6 Modulation
Samantha Chalmers¹, Sayra Garcia ¹, Jeanette Ampudia ², Cherie Ng ², Stephen Connelly ² and Chaim Putterman ³, ¹Albert Einstein College of Medicine, Bronx, NY, ²Equillium, Inc, San Diego, CA, ³Albert Einstein College of Medicine, New York, NY
Background/Purpose: CD6 is a co-stimulatory receptor on T cells, that binds to activated leukocyte cell adhesion molecule (ALCAM), a ligand expressed on antigen presentation cells…
Abstract Number: 1564 • 2019 ACR/ARP Annual Meeting
Renal Arteriosclerosis Predicts Cardiovascular Disease in Lupus Nephritis
Shivani Garg¹, Sarah Panzer ², Karen Hansen ³, Callie Plafkin ⁴, Maureen Smith ² and Christie Bartels ¹, ¹University of Wisconsin School of Medicine and Public Health, Madison, WI, ²UW-Madison, Madison, ³UW Madison, Madison, ⁴UW Health, Madison
Background/Purpose: Patients with lupus nephritis (LN) have a 9-fold higher risk of cardiovascular disease (CVD), highlighting the urgent need to target CVD prevention. Studies in…
Abstract Number: 2556 • 2019 ACR/ARP Annual Meeting
Histologic Findings from Paired Renal Biopsies and Clinical Outcomes: Results from a Single Site in the Phase III Study of Abatacept in Patients with Proliferative LN
Ana Malvar¹, Valeria Alberton ², Cecilia Recalde ², Sheng Gao ³ and Michael Maldonado ³, ¹Hospital Fernandez; Organización Maedica de Investigación, Buenos Aires, Argentina, ²Hospital Fernandez, Buenos Aires, Argentina, ³Bristol-Myers Squibb, Princeton, NJ
Background/Purpose: Current therapeutic management of active Class III or IV proliferative LN relies on the use of maintenance therapy following induction. The optimal method for…
Abstract Number: 72 • 2019 ACR/ARP Annual Meeting
The Single-cell Transcriptomic Landscape of NZB/W Murine Lupus at Early and Late Stages of Disease
Paul Hoover¹, Tom Eisenhaure ², David Lieb ², Anne Davidson ³ and Nir Hacohen ², ¹Brigham and Women's Hospital, Boston, MA, ²Broad Institute, Cambridge, MA, ³Feinstein Institutes for Medical Research, Manhasset
Background/Purpose: Lupus nephritis is a complex and heterogeneous disease characterized by infiltrating immune cells in damaged kidney tissue. While mouse models have enabled mechanistic studies…
Abstract Number: 1566 • 2019 ACR/ARP Annual Meeting
HER2 as a Biomarker of Proliferative Lupus Nephritis in Children
Kathleen Sullivan¹, Jonathan Burnham ², Kathleen O'Neil ³, Laura Schanberg ⁴, Emily von Scheven ⁵, Marisa Klein-Gitelman ⁶ and Patricia Costa Reis ⁷, ¹Children's Hospital of Philadelphia, Philadelphia, PA, ²The Children's Hospital of Philadelphia, Philadelphia, PA, ³Indiana University, Indianapolis, IN, ⁴Duke University Medical Center, Durham, NC, ⁵UCSF, San Francisco, CA, ⁶Lurie Children's Hospital, Chicago, IL, ⁷Hospital de Santa Maria, Lisbon, Portugal
Background/Purpose: Lupus nephritis is a common feature of SLE and confers a poor prognosis. 20-50% of patients with lupus nephritis ultimately develop chronic kidney disease…
Abstract Number: 2561 • 2019 ACR/ARP Annual Meeting
Deep Remission During Induction Therapy for Lupus Nephritis Prevents Damage Accrual and Associates with the Baseline Proportions of Peripheral Treg, CD8+ T Cells, and NKT-like Cells
Jun Kikuchi¹, Hironari Hanaoka ¹, Shuntaro Saito ¹, Tatsuhiro Oshige ¹, Kazuoto Hiramoto ¹, Yuko Kaneko ¹, Noriyasu Seki ², Hideto Tsujimoto ² and Tsutomu Takeuchi ¹, ¹Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan, ²Mitsubishi Tanabe Pharma Corporation Sohyaku. Innovative Research Division, Toda-shi, Saitama, Japan
Background/Purpose: chievement of renal remission has been the target of the induction therapy in patients with active lupus nephritis (LN). Deep remission (DR) defined as…
Abstract Number: 639 • 2019 ACR/ARP Annual Meeting
African-American Risk of Proteinuria After SLE Diagnosis Increases Throughout Thirty Years of Followup
Michelle Petri¹ and Jessica Li ¹, ¹Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: African-Americans lupus nephritis is more common than in Caucasians, more severe and more likely to lead to end stage renal disease. We asked whether…
Abstract Number: 1569 • 2019 ACR/ARP Annual Meeting
Poor Long-term Renal Outcome in Systemic Lupus Erythematosus Without Abnormal Urinalysis: A Possible Link with Silent Lupus Nephritis
Hironari Hanaoka¹, Jun Kikuchi ², Shuntaro Saito ¹, Hiroshi Takei ³, Kazuoto Hiramoto ¹, Tatsuhiro Oshige ¹, Noriyasu Seki ⁴, Hideto Tsujimoto ⁴, Yuko Kaneko ¹ and Tsutomu Takeuchi ⁵, ¹Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan, ²Keio Universitiy School of Medicine, Tokyo, Japan, ³Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, ⁴Mitsubishi Tanabe Pharma Corporation Sohyaku, Tokyo, ⁵Keio University School of Medicine, Tokyo, Japan
Background/Purpose: Background/Purpose: It has been well investigated that patients with lupus nephritis (LN) have worse prognosis than those without. Recently reported, about 20% of SLE…
Abstract Number: 2567 • 2019 ACR/ARP Annual Meeting
Prospective Evaluation of American Academy of Ophthalmology Low Dose Hydroxychloroquine Recommendation in Stable Lupus Nephritis with High-Risk Retinopathy: Lipid Profile and Flare Rates
Tatiana Pedrosa ¹, Sandra G. Pasoto ¹, Emily Yuki², Nadia Aikawa ¹, Eduardo Borba ¹, Julio Ferreira Filho ¹, Pedro Carricondo ³, Caio Zanetti ¹, Paola Conde ¹, Nicole Fontoura ¹, Paschoalina Romano ⁴, Valdemir Carvalho ⁵, Clovis Silva ⁶ and Eloisa Bonfa ⁷, ¹Rheumatology Division, Hospital das Clinicas, Faculdade de Medicina da Universidade de Sao Paulo (HCFMUSP), Sao Paulo, Brazil., Sao Paulo, Brazil, ²Rheumatology Division, Hospital das Clinicas, Faculdade de Medicina da Universidade de Sao Paulo (HCFMUSP), Sao Paulo, Brazil., São Paulo, Brazil, ³Ophtalmology Division, Hospital das Clinicas, Faculdade de Medicina da Universidade de Sao Paulo (HCFMUSP), Sao Paulo, Brazil., Sao Paulo, Brazil, ⁴Division of Central Laboratory, Hospital das Clinicas, Faculdade de Medicina da Universidade de Sao Paulo (HCFMUSP), Sao Paulo, Brazil., Sao Paulo, Brazil, ⁵Fleury Group, Sao Paulo, Brazil, Sao Paulo, Brazil, ⁶Pediatric Rheumatology Unit, Hospital das Clinicas, Faculdade de Medicina da Universidade de Sao Paulo (HCFMUSP), Sao Paulo, Brazil., Sao Paulo, Brazil, ⁷Rheumatology Division, Hospital das Clinicas, Faculdade de Medicina da Universidade de Sao Paulo (HCFMUSP), Sao Paulo, Brazil., Sao Paulo, Sao Paulo, Brazil
Background/Purpose: Hydroxychloroquine (HCQ) is the most well established therapy for SLE, as it provides several beneficial properties, such as favorable effects on lipid profile, reduced…
Abstract Number: 653 • 2019 ACR/ARP Annual Meeting
Newly Diagnosed Lupus Nephritis in Elderly Predicts Good Renal Outcome: A Distinct Disease Subset from Young-onset Lupus Nephritis
Kazuoto Hiramoto¹, Hironari Hanaoka ¹, Jun Kikuchi ¹, Shuntaro Saito ¹, Hiroshi Takei ², Tatsuhiro Oshige ¹, Noriyasu Seki ³, Hideto Tsujimoto ³, Yuko Kaneko ¹ and Tsutomu Takeuchi ¹, ¹Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan, ²Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, ³Mitsubishi Tanabe Pharma Corporation Sohyaku. Innovative Research Division, Toda-shi, Saitama, Japan
Background/Purpose: Elderly-onset SLE is recognized to be benign disease entity with a favorable nature course. Although late-onset lupus nephritis (LN), long interval between onset of…
Abstract Number: 1733 • 2019 ACR/ARP Annual Meeting
Long-term Renal Survival of Pediatric Onset Lupus Patients in a Population-Based Cohort
Catherine Park ¹, Janet Figueroa ¹, Cristina Drenkard ¹, Laura Plantinga ¹, Larry Greenbaum ² and S Sam Lim¹, ¹Emory University, Atlanta, GA, ²Emory University and Children's Healthcare of Atlanta, Atlanta, GA
Background/Purpose: Compared to adult-onset disease, pediatric-onset SLE (p-SLE) has more severe renal involvement. There are no population-based, long-term follow-up studies of pediatric lupus nephritis (LN)…
Abstract Number: 2568 • 2019 ACR/ARP Annual Meeting
Iguratimod Is an Alternative Option for Refractory Lupus Nephritis: A Preliminary Observational Study
Qingran Yan¹, Chunde Bao ², Yuening Kang ¹, Qiong Fu ¹ and Ran Wang ¹, ¹Department of Rheumatology, Renji Hospital, Shanghai Jiaotong University School of medicine, Shanghai, China (People's Republic), ²Department of Rheumatology, Renji Hospital, Shanghai Jiaotong University School of medicine, Shanghai, Shanghai, China (People's Republic)
Background/Purpose: Despite significant advances in the management of patients with lupus nephritis (LN), a significant proportion of patients either do not respond to first-line immunosuppressive…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].